The oxazolidinones

Current Infectious Disease Reports

Volumn 4, Issue 1, 2002, Pages 17-27

  Evans, Gerald A ^a  

^a KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Antimicrob Agent; Infective Endocarditis; Linezolid; Teicoplanin; Vancomycin

Indexed keywords

EID: 0002545924     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-002-0063-6     Document Type: Article

References (50)

1. Brickner SJ: Oxazolidinone antibacterial agents. Curr Pharmaceutical Design 1996, 2:175–194.
2. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998, 42:3251–3255.
3. Shinabarger DL, Marotti KR, Murray RW, et al.: Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997, 41:213–236.
4. Lin AH, Murray RW, Vidmar TJ, Marotti KR: The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997, 41:2127–2131.
5. Patel U, Yan YP, Hobbs FW, et al.: Oxazolidinones mechanism of action: inhibition of the first peptide bond formation. J Biol Chem 2001, 276:37199–37205. A systematic and organized approach to uncovering the oxazolidinone mechanism of action.
6. Prystowsky J, Siddiqui F, Chosay J, et al.: Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001, 45:2154–2156.
7. Xiong L, Kloss P, Douthwaite S, et al.: Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol 2000, 182:5325–5331.
8. Gonzales RD, Schreckenberger PC, Graham MB, et al.: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001, 357:1179. Important first report of resistance to oxazolidinines arising in the clinical context.
9. Tsiodras S, Gold HS, Sakoulas G, et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207–208. Careful analysis of rRNA genome in resistant isolates confirms that same changes seen in laboratory-derived strains confer resistance in these clinical isolates.
10. Noskin GA, Siddiqui F, Stosor V, et al.: In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999, 43:2059–2062.
11. Rybak MJ, Hershberger E, Moldovan T, Grucz RG: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000, 44:1062–1066.
12. Doern GV, Heilmann KP, Huynh HK, et al.: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother 2001, 45:1721–1729. A sobering report on the emerging problems with antibiotic-resistant pneumococci and a preview of the activity of newer agents against resistant strains.
13. Zaoutis T, Moore LS, Furness K, Klein JD: In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates. Antimicrob Agents Chemother 2001, 45:1952–1954.
14. Wallace RJ, Brown-Elliott BA, Ward SC, et al.: Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001, 45:764–767.
15. Citron DM, Warren YA, Tyrrell KL, et al.: Comparative in vitro activity of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria [abstract E-1417]. In In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 2001:193.
16. Brown-Elliott BA, Wallace RJ, Blinkhorn R, et al.: Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis 2001, 33:1433–1434.
17. Brown-Elliott BA, Ward SC, Crist CJ, et al.: In vitro activities of linezolid against multiple nocardia species. Antimicrob Agents Chemother 2001, 45:1295–1297.
18. Heine HS, Dicks R, Andrews G: In vitro activity of oritavancin (LY333328), levofloxacin, GAR936 and linezolid against strains of Bacillus anthracis [abstract E-524]. In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 2001:173.
19. Biedenbach DJ, Jones RN: Disk diffusion interpretive criteria and quality control recommendations for testing linezolid and eperezolid with commercially prepared reagents. J Clin Microbiol 1997, 35:3198–3202.
20. NCCLS: Performance Standards for Antimicrobial Susceptibility Testing; Eleventh Informational Supplement. Wayne, PA: NCCLS; 2001:NCCLS document M100-S11.
21. Livermore DM, Mushtaq S, Warner M: Susceptibility testing with linezolid by different methods in realtion to published ‘general breakpoints’. J Antimicrob Chemother 2001, 48:452–454.
22. Gee T, Ellis R, Marshall G, et al.: Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001, 45:1843–1846.
23. Slatter JG, Stalker DJ, Feenstra KL, et al.: Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab Dispos 2001, 29:1136–1145.
24. Lasher Sisson T, Jungbluth GL, Stalker DJ, Hopkins NK: Effect of age and gender on the single-dose pharmacokinetics of linezolid [abstract 1194]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; 1999:32.
25. Kearns GL, Abdel-Rahman SM, Blumer JL, et al., and the Pediatric Pharmacology Research Unit Network: Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000, 19:1178–1184.
26. Stalker DJ, Wajszczuk CP, Batts DH: Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days [abstract A-116].In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto; 1997:23–24.
27. Wilcox MH, Kite P, Mills K, Sugden S: In situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilm. J Antimicrob Chemother 2001, 47:171–175. A new methodology for evaluating the potential for antibiotics to be useful in treating catheter-related infections.
28. Cammarata SK, Le V, Oliphant TH, et al.: Incidence of Clostridium difficile-related complications during clinical trials of linezolid, an oxazolidinone [abstract 947]. In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto; 2000:411.
29. Pai MP, Gonzales RD, Petrolati JM, et al.: Risk factors associated with the development of enterococcal resistance to linezolid [abstract K-1194].In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 2001:409.
30. Craig WA: Does the dose matter? Clin Infect Dis 2001, 33(Suppl 3):S233-S237.
31. Humphrey W, Shattuck M, Kolbasa K, et al.: Pharmacodynamic (PD) parameters of linezolid assoociated with efficacy vs. Streptococcus pneumonaie-induced acute otitis media (AOM) in gerbils [abstract A-2096]. In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 2001:34.
32. Munckhof WJ, Giles C, Turnidge JD: Post-antibiotic growth suppression of linezolid against gram-positive bacteria. J Antimicrob Chemother 2001, 47:879–883.
33. Sweeney M, Hamel J, Stapert D, et al.: Activity of linezolid combined with quinolones and novobiocin [abstract E-330]. In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 2001:170.
34. Coyle E, Cha R, Rybak MJ: Influence of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin A release [abstract A-2197]. In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapyv. Chicago; 2001:38.
35. Stevens DL, Smith LG, Bruss JB, et al., for the Linezolid Skin and Soft Tissue Infections Study Group: Randomized comparison of linezolid versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000, 44:3408–3413.
36. Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG, and the Linezolid Nosocomial Pneumonia Study Group: Linezolid versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001, 32:402–412.
37. Li Z, Willke RJ, Pinto LA, et al.: Comparison of length of hospital stay for patients with known or duspected methicillin-tesistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001, 21:263–274.
38. Kaplan SL, Patterson L, Edwards KM, et al., and the Linezolid Pediatric Pneumonia Study Group: Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr Infect Dis J 2001, 20:488–494.
39. Cammarata SK, Oliphant TH, Hempsall KA: Linezloid efficacy in the treatment of ventilator-associated nosocomial pneumonia [abstract K-1469]. In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 2001:436.
40. Wilcox M, Tang T, Hafkin B: Linezolid versus teicoplanin for the treatment of hospitalized patients with gram-posiitve infections [abstract L-1481]. In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 2001:471.
41. Hartman CS, Leach TS, Kaja RW, et al.: Linezolid in the treatment of vancomycin-resistant enterococcus: a dose comparative, multicenter phase III trial [abstract 2235]. In In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto; 2000:488.
42. Christiansen E, Starlin R, Little R, Stanley S: Successful treatment of vancomycin-resistant enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001, 32:1373–1375.
43. Zeana C, Kubin CJ, Della-Latta P, Hammer SM: Vancomycinresistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001, 33:477–482.
44. Arellano FM: Linezolid and reversible myelosuppression [response]. JAMA 2001, 286:1973–1974.
45. Green SL, Maddox JC, Huttenbach ED: Linezolid and reversible myelosuppression. JAMA 2001, 285:1291. Observant analysis of a potential safety issue with oxazolidinones along with useful clinical clues to aid in its detection.
46. Abena PA, Mathieux VG, Schieff JM, et al.: Linezolid and reversible myelosuppression [response]. JAMA 2001, 286:1973.
47. Kuter DJ, Tillotson GS: Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001, 21:1010–1013. A critical analysis of the issue of myelosuppression from postmarketing surveillance data of linezolid use and the possible confounding variables in assessing a causal relationship.
48. Antl EJ, Hendershot PE, Batts DH, et al.: Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001, 41:552–562.
49. Humphrey SJ, Curry JT, Turman CN, Stryd RP: Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid. J Cardiovasc Pharmacol 2001, 37:548–563.
50. Leach TS, Lobeck FG, Todd WM, Hafkin B: Lack of serotonin syndrome in Phase III patients receiving linezolid and a selective serotonin reuptake inhibitor [abstract 64]. In Abstracts of the 38th Annual Meeting of the Infectious Disease Society of America. New Orleans; 2000.